This pilot clinical trial studies how well carbon C 11 choline positron emission tomography (PET) works in assessing post-treatment true tumor progression from pseudo-progression in patients with high-grade gliomas. Carbon C 11 choline PET may improve upon the usual scans at diagnosing or monitoring the type of cancer and distinguish true tumor growth from inflammation more accurately.
Additional locations may be listed on ClinicalTrials.gov for NCT02849171.
See trial information on ClinicalTrials.gov for a list of participating sites.
PRIMARY OBJECTIVES:
I. To determine the distribution of carbon C 11 choline (11C-CH) in high-grade glioma lesions with magnetic resonance imaging (MRI) findings concerning for pseudoprogression versus (vs) true tumor progression following radiotherapy (with or without concurrent therapy).
II. To investigate the correlation between 11C-CH standardized uptake value (SUV) measures and MRI follow-up outcomes in patients with high-grade glioma lesions with changes concerning for pseudoprogression vs true tumor progression following treatment with radiation (with or without concurrent therapy).
OUTLINE:
Within 2 weeks of standard of care MRI, patients receive carbon C 11 choline intravenously (IV). After 30 minutes, patients undergo PET/computed tomography (CT) scan over 30 minutes.
After completion of study, patients are followed up for 11 months.
Trial PhaseNo phase specified
Trial Typediagnostic
Lead OrganizationMemorial Sloan Kettering Cancer Center
Principal InvestigatorRonald G. Blasberg
